Adage Capital Partners’s Voyager Therapeutics VYGR Stock Holding History

Adage Capital Partners’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-375,000	Closed	-$7.18M	–	763
2019 Q1	$7.18M	Hold	375,000	–	–	0.02%	572
2018 Q4	$3.52M	Hold	375,000	–	–	0.01%	638
2018 Q3	$7.09M	Sell	375,000 -100,000	-21%	-$1.92M	0.02%	592
2018 Q2	$9.28M	Hold	475,000	–	–	0.02%	575
2018 Q1	$8.93M	Sell	475,000 -180,000	-27%	-$3.89M	0.02%	573
2017 Q4	$10.9M	Sell	655,000 -320,000	-33%	-$5.49M	0.02%	557
2017 Q3	$20.1M	Sell	975,000 -25,000	-3%	-$282K	0.05%	416
2017 Q2	$8.96M	Hold	1,000,000	–	–	0.02%	583
2017 Q1	$13.2M	Buy	1,000,000 +553,920	+124%	+$6.72M	0.03%	487
2016 Q4	$5.68M	Buy	446,080 +246,080	+123%	+$3.16M	0.02%	597
2016 Q3	$2.4M	Buy	200,000 +100,000	+100%	+$1.35M	0.01%	643
2016 Q2	$1.1M	Hold	100,000	–	–	﹤0.01%	653
2016 Q1	$873K	Buy	+100,000	New	+$1.13M	﹤0.01%	667

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners's VYGR Position: Q2 2019 in Review

Adage Capital Partners sold out of Voyager Therapeutics (VYGR) in Q2 2019, closing a stake of 375,000 shares — an estimated $7.18M sold.

Adage Capital Partners first reported a position in VYGR in Q1 2016 and held it in 13 quarters. The position peaked at $20.1M in Q3 2017. 125 funds tracked by Wall St. Rank hold VYGR as of Q2 2019.

Adage Capital Partners reported no remaining Voyager Therapeutics position as of Q2 2019 after selling out during the quarter.
Adage Capital Partners sold 375,000 Voyager Therapeutics shares in Q2 2019, an estimated $7.18M.
Adage Capital Partners first reported a position in Voyager Therapeutics in Q1 2016 and held it in 13 quarters.
Adage Capital Partners's Voyager Therapeutics position peaked at $20.1M in Q3 2017.
125 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2019.

Based on Adage Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.